Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

Background Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury. Reportedly, nonsteroidal anti-inflammatory drugs (NSAIDs) mitigate DAergic neurotoxicity in rodent models of PD. Consistent with these findings, epidemiological analysis indicated that certain NSAIDs may prevent or delay the progression of PD. However, a serious impediment of chronic NSAID therapy, particularly in the elderly, is gastric, renal and cardiac toxicity. Nitric oxide (NO)-donating NSAIDs, have a safer profile while maintaining anti-inflammatory activity of parent compounds. We have investigated the oral activity of the NO-donating derivative of flurbiprofen, [2-fluoro-α-methyl (1,1'-biphenyl)-4-acetic-4-(nitrooxy)butyl ester], HCT1026 (30 mg kg-1 daily in rodent chow) in mice exposed to the parkinsonian neurotoxin MPTP. Methods Ageing mice were fed with a control, flurbiprofen, or HCT1026 diet starting ten days before MPTP administration and continuing for all the experimental period. Striatal high affinity synaptosomial dopamine up-take, motor coordination assessed with the rotarod, tyrosine hydroxylase (TH)- and dopamine transporter (DAT) fiber staining, stereological cell counts, immunoblotting and gene expression analyses were used to assess MPTP-induced nigrostriatal DAergic toxicity and glial activation 1-40 days post-MPTP. Results HCT1026 was well tolerated and did not cause any measurable toxic effect, whereas flurbiprofen fed mice showed severe gastrointestinal side-effects. HCT1026 efficiently counteracted motor impairment and reversed MPTP-induced decreased synaptosomal [3H]dopamine uptake, TH- and DAT-stained fibers in striatum and TH+ neuron loss in subtantia nigra pars compacta (SNpc), as opposed to age-matched mice fed with a control diet. These effects were associated to a significant decrease in reactive macrophage antigen-1 (Mac-1)-positive microglial cells within the striatum and ventral midbrain, decreased expression of iNOS, Mac-1 and NADPH oxidase (PHOX), and downregulation of 3-Nitrotyrosine, a peroxynitrite finger print, in SNpc DAergic neurons. Conclusions Oral treatment with HCT1026 has a safe profile and a significant efficacy in counteracting MPTP-induced dopaminergic (DAergic) neurotoxicity, motor impairment and microglia activation in ageing mice. HCT1026 provides a novel promising approach towards the development of effective pharmacological neuroprotective strategies against PD.

Consistent with the inflammation hypothesis, epidemiological analysis has indicated that nonsteroidal antiinflammatory drugs (NSAIDs) may prevent or delay the progression of PD [6,7,[45][46][47][48][49][50][51][52]. NSAIDs are among the most widely used therapeutic agents for the treatment of pain, fever and inflammation. Their effects are largely attributed to the inhibition of the enzymatic activity of COXs, of which there are two isoforms, COX-1 and COX-2. Both enzymes are responsible for arachidonic acid conversion in different prostaglandins (PGs) [53,54]. While COX-1 is constitutively expressed in most tissues, COX-2 is induced during pathophyiological responses to inflammatory stimuli [55]. Both mixed and selective COX-2 inhibitors have been reported to mitigate DAergic neurotoxicity in experimental models of PD; or to reduce LPS-induced neuronal damage [recently reviewed in [45,46]]. Besides targeting COXs, NSAIDs can act in a COX-independent way, which includes activation of the nuclear factor peroxisome proliferator-activated receptor-γ (PPAR-γ), the protection against glutamate and 1-methyl-4-phenylpyrdinium ion (MPP + ) toxicity, scavenging hydroxyl and NO radicals and dopamine-quinone formation [18,[45][46][47][48].
We herein report that HCT1026 has a safer profile and a greater efficacy than its parent compound in rescuing nigrostriatal DAergic neurons from MPTP neurotoxicity and that a shift in microglial pro-inflammatory phenotype is involved in this phenomenon. HCT1026 is safe at the gastrointestinal level, and it has been tested in humans; it is effective on oral administration, and it is thus suited for long-term treatment, thereby representing a promising approach towards the development of effective pharmacological neuroprotective strategies against PD.

Animals
Young adult (2-5 months of age) and ageing (9-11 month-old) male C57BL/6 (Charles River, Calco, Italy) housed (5 mice/cage) in a temperature (21-23°C), humidity (60%), and light (50/50 light:dark cycle, lights on at 06.00 a.m) controlled room, with controlled access to food and water, were allowed to acclimate one week before the start of the experimental protocol. Studies were conducted in strict accord with the Guide for the Care and Use of Laboratory Animals (NIH), and approved by the Review Boards of the OASI Institute (Troina, Italy). The authors further attest that all efforts were made to minimize the number of animal used and their suffering.

Drug administration
The drugs were compounded in the chow (Teklad 2018 diet, Harlan), the schedule of administration defined according to a pilot experiment conducted to monitor daily food intake, and the dose selected as that producing a full anti-inflammatory effect [66]. The following doses were used: HCT1026 190 ppm in the diet or 30 mg kg -1 day -1 per animal; flurbiprofen 120 ppm or 20 mg kg -1 day -1 per animal Flurbiprofen dose was equimolar to HCT1026 (MW HCT1026:361.4; flubiprofen:244.3, ratio HCT1026/flurbiprofen = 1.48). Plain teklas 2018 chow was used as control diet. The treatment started 7-10 d days prior MPTP administration and thoroughout the entire experiment. Food consumption was monitored daily, diets were weighed and and food intake calculated daily, body weights recorded.

MPTP administration
Both the acute [67] and the subchronic [68] MPTP injection paradigms, and three different dose-levels (5, 15, or 30 mg kg -1 MPTP-HCl measured as a free base), were selected in order to verify the ability of a preventive administration of HCT1026 to exert neuroprotective effects against MPTP-induced DAergic toxicity ( Table 1). The same lot of MPTP-HCl (Sigma, Italy) was used for one experimental series. In a first series of experiments, in the acute protocol, MPTP was systemically injected (i.p.) at a dose of 15 mg/kg -1 , 4 times a day, at 2 hr intervals [28,36]. In the subchronic regimen, increasing doses of MPTP were administrated i.p. at 24-h interval, for 5 consecutive days and mice sacrificed 7 d post-treatment. The dose of 15 mg/kg -1 day -1 and the subchronic regimen were then selected to assess longterm effects of HCT1026 in all subsequent experiments in ageing mice [32,42]. Groups of mice fed with the different diets and injected with vehicle (0.9% saline, 2 ml kg -1 intraperitoneally), served as controls (see Table 1). MPTP handling and safety measures were in accordance with published guidelines according to Jackson-Lewis and Przedborski [69].

Sacrifice and tissue processing
Controls and MPTP-treated mice were killed at selected times ranging from 0-40 days post-MPTP treatment (dpt). To study early drug effects on microglia activation during the active degeneration phase, groups of mice were studied 1-7 dpt (Table 1). To monitor the severity of nigrostriatal damage and the survival/neurorescue of nigrostrial neurons, group of mice were studied 7, 21, 30 and 40 dpt. MPTP-induced motor deficit was assed with the Rotarod, at -7, + 1, + 3 and + 7 dpt. For neurochemical determinations, heads were cooled by rapid immersion in liquid nitrogen. Thereafter, striata of both sides and ventral mesencephalon, were rapidly removed and frozen at -80°C for subsequent determinations [8]. For histopathological determinations, mice were deeply anesthetized and perfused transcardially, as reported in full details [8].

Determination of drug plasma level
Blood samples were taken at the indicated times and plasma samples were frozen and stored at -80°until the analysis was performed. Plasma 0.1 ml was mixed with 10 μl ketoprofen (internal standard, 1 mg ml -1 stock solution in methanol) and 400 μl of cold methanol/acetonitrile (1:1) mixture, vortexed and centrifuged at 13,000 × g for 10 min at 25°C. HPLC analysis was  [70].

Motor behavior analysis with the rotarod
An accelerating rotarod (five-lane accelerating rotarod; Ugo Basile, Comerio, Italy) was used to measure motor balance and coordination in mice. Mice have to keep their balance on a horizontal rotating rod (diameter, 3 cm) and rotation speed was increased every 30 sec by 4 rpm. Five mice were tested at the same time, separated by large disks. A trial starts when the mouse is placed on rotating rod, and it stops when the mouse falls down or when 5 min are completed. Falling down activates a switch that automatically stops a timer. The testing day, each mouse is submitted to 5 trials with an intertrial interval of 30 min. Mice housed five per cage were acclimated to a 12 h shift in light/dark cycle so that the exercise occurred during the animals normal wake period. Saline-and MPTP-treated mice fed with a control or HCT1026 diet (10/experimental group) were assessed for their Rotarod performance on day -7, +1, + 3 and +7 dpt.

High-affinity [ 3 H]dopamine uptake assay
Left and right striata were homogenized in ice-cold prelysis buffer (10 mM Tris, pH 7.5, and 0.32 M sucrose) using a Teflon pestle-glass mortar and homogenized tissue centrifuged for 10 min at 1000 × g at 4°C to remove nuclei. The supernatant containing the synaptosomes was collected and aliquots removed for the determination of protein content [71] and dopamine uptake (total high affinity and mazindol non-inhibitable  [8].
All antibodies, whether used for single or dual labeling procedures, were visualized by immunofluorescence, except for TH-Ab that was also visualized using immunoperoxidase. Adjacent tissue was also stained with cresyl violet to validate TH neuron survival [8,73,74]. Sections were incubated with the indicated dilutions of the antibodies, either alone or in combination as described. After 3 (× 5 min) washes in PBS, primary antibodies were revealed with specific FITC and CY3 conjugated secondary antibodies 1:100-1:200 dilution. (60 min at room temp). After 3 (× 5 min) washes in PBS, sections were mounted with Gel mounting solution (Biomeda corp. Foster City, CA, USA). In all of these protocols, blanks were processed as for experimental samples except that the primary antibodies were replaced with PBS.

Loss of TH-positive neurons and striatal DAergic innervation
Loss of TH-positive (TH + ) SNpc neurons was determined by serial section analysis of the total number of TH + cells counted throught the entire rostro-caudal (RC) axis of the murine SNpc (Bregma coordinates: -2.92, -3.08, -3.16, -3.20, -3.40 and -3.52) according to Franklin and Paxinos [72] at 7, 21, 30 and 40 days post-MPTP (dpt) or saline injection [8]. Cell counting was done in both side of the brain for each animal, and then right and left values were added to generate a total DA SNpc neuron count, in a total of five animals per experimental group. TH-labeled neurons were scored as positive only if their cell-body image included well defined nuclear counterstaining. Estimates of total TH + -stained and cresyl-violet-stained neurons in the SNpc were calculated using the Abercrombie's correction [74]. The total number of TH + cell bodies was estimated and examined by two independent researchers, in a blind fashion. Loss of striatal DAergic innervation was assessed by quantification of TH-and DAT-immunofluorescent (IF) signal intensity in 10 μm-thick coronal sections located at 0.5, 0.8 and 1.1 mm from bregma, and analyses carried out by confocal laser miscroscopy as described [8].

Confocal laser microscopy and image analysis
Sections labeled by immunofluorescence were visualized and analyzed with a confocal laser scanning microscope LEICA TCS NT (Version 1.0, Leica Lasertechnik GmBH, Heidelberg, Germany), equipped with an argon/ krypton laser using 10 ×, 20 ×, and 40 × and 100 × oilimmersion objectives. Pinhole was set at 1-1.3 for optical sections of 0.48-0.5 μm. For TH + and DAT + fibers in striatum, fluorescence intensity per unit of surface area was determined in 10 randomly selected fields (250.000 μm 2 ) using computer-assisted image analysis software (LEICA). Single lower power scans were followed by 16 to 30 serial optical sectionings. Laser attenuation, pinhole diameter, photomultiplier sensitivity, and off-set were kept constants. The average fluorescence intensity (pixel, mean ± SEM per unit surface area) was measured throught the stack. Within the same stacks, the background pixel intensity in areas devoid of fibers/cells was determined and substracted. For assessment of reactive microglial cell number, ameboidshaped Mac-1 + cells [75] were counted in striatal and SNpc coronal sections, cell counts averaged for each animal and the mean number of cells per mm 2 per animal was estimated. A comparable countable area ranging from 1.90 mm 2 to 2.00 mm 3 was analyzed in the different MPTP groups. Double-labelled cells with iNOS and Mac-1, were counted and expressed as above. Dual stained TH + 3-NT + cells were counted and values expressed as a percent double-stained TH + NT + /TH + neurons. Each label was analyzed on a total of 12 sections per mice and in at least 4 mice per group. Analyses were performed by two independent researchers blind to the experiment.

Western blot analysis
Protein extracts were prepared for striatum and ventral midbrain (which included the SNpc) (left and right sides) at the indicated time-intervals after saline or MPTP injections (n = 3 per group). The tissue samples were homogenized in lysis buffer (0.33 M sucrose, 8 mM Hepes, pH 7.4 and protease inhibitors) and quantified using the BCA protein determination method (Bio-Rad, Hercules, CA). Protein samples were diluted to equivalent volumes containing 20 μg of protein and boiled in an equal volume of Laemli SDS boiling buffer (Sigma) for 10 min. Samples were loaded into a 9-12% SDS-polyacrilamide gel and separated by electrophoresis for 3 h at 100 V. Proteins were transferred to polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ) for 1.5 h at 300 mA. After blocking of nonspecific binding with 5% nonfat dry milk in TBST, the membranes were then probed with the following primary antibodies: rabbit anti-TH (Chemicon); rat anti-DAT (Millipore), rabbit anti-Mac1 (AbCam), mouse anti-gp91phox (BD Transduction Laboratories), β-actin (Cell Signaling). After incubation at room temperature for 1 hr, membranes were washed and treated with appropriate secondary antibodies conjugated with horseradish peroxidase (HRP) and blot were exposed onto radiographic film (Hyperfilm; Amersham Bioscience). Membranes were reprobed for β-actin immunolabeling as an internal control. The bands from the Western blots were densitometrically quantified on X-ray films (Image-Quantity One). The data from experimental band were normalized to β-actin, before statistical analysis of variance and values expressed as % of saline-injected controls.

Statistical analysis
Data were analyzed by means of two-way analysis of variance (ANOVA), with group and time as independent variables and given as mean±SEM. Striatal neurochemical data (nmol or pmol mg protein -1 ) are expressed as % of controls. Comparisons a posteriori between different experiments were made by Student-Newman-Keuls t-test.

Results
HCT1026 preventive administration counteracts MPTPinduced down-regulation of high affinity synaptosomial DA uptake in the striatum We first assessed the short-term effect of the control and medicated diets on striatal high affinity synaptosomial [ 3 H]DA uptake ( Figure 1A,B), a sensitive quantitative indicator of DAergic axonal terminal density [76]. In 2-3 month-old mice fed with flurbiprofen or HCT1026 diets and treated with saline, DA uptake levels were not different compared to saline-treated mice fed with the control diet. On the other hand, in mice fed with a control diet and exposed to the subacute MPTP (15 mg kg -1 , 4 times a day, at 2 h intervals), we observed after 7 d the severe decrease (-75%) of striatal DA uptake ( Figure 1A). In mice fed with flurbiprofen and treated with MPTP, a certain degree of protection was observed, as reflected by the less severe decrease (-54%) of DA uptake. On the other hand, HCT1026 afforded a greater protection, as illustrated by the significantly (p < 0.05) smaller (-25%) decrease of [ 3 H] DA uptake levels as compared to mice fed with the control or flurbiprofen diets. With the subchronic (administration of MPTP at 24-h interval, for 5 consecutive days) regimen, increasing the daily doses of MPTP resulted in a dose-dependent loss of DA uptake levels ( Figure 1B). By contrast, mice fed with HCT1026 and exposed to 5 mg kg -1 day -1 for five days, were resistant to MPTP-induced DAergic toxicity, as revealed by the counteraction of the almost 38-48% loss of striatal DA uptake measured in mice fed with the control or flurbiprofen diets. In addition, mice exposed to higher (15 and 30 mg kg -1 day -1 ) MPTP doses and fed with control or flurbiprofen diets exhibited far greater (p < 0.05) decreases of striatal DA uptake compared with mice fed with HCT1026 ( Figure 1B).
The preventive oral administration with HCT1026 was well tolerated and did not cause any measurable toxic effect throught the treatment, whereas flurbiprofen-fed mice showed severe gastrointestinal side-effects (bleeding). Due to flurbiprofen toxicity, only HCT1026 was studied in the long-term experimental protocol.
To more closely mimick PD condition, we next assessed the longterm efficacy and safety of HCT1026 in ageing (9-11 month-old) mice. Reportedly, the process of ageing increases DAergic vulnerability to MPTP and limits the repair capacity of the nigrostriatal DAergic system [77,78]. We thus selected the subchronic MPTP regimen, at a dose of 15 mg/kg [28,32,42]. Consistent with previous findings [77,78], ageing mice fed with a control diet did not recovered from MPTP insult, as revealed by an almost 70-75% decrease of DA uptake levels measured up to 40 dpt, whereas in mice fed with HCT1026, a significant degree of protection was measured, as reflected by the significant amelioration of striatal DA uptake levels at all time-points studied (Figure 1C). These data indicate that the neuroprotective activity of HCT1026 was maintained up to 40 dpt. In addition, the longterm administration of HCT1026 does not cause any measurable toxic effects.

HCT1026 inhibits MPTP-induced motor impairment
To verify the ability of HCT1026 to affect MPTP-induced impairment of motor coordination [42,79,80], we assessed the ability to maintain the balance on a rotating cylinder and to adapt to the rate of locomotor activity, by using the Rotarod test, as described ( Figure 1D). Saline-and MPTPtreated mice fed with a control or HCT1026 diet (n = 10/ experimental group) were assessed for their Rotarod performance one week before saline or MPTP treatment (day -7) and + 1, + 3 and + 7 d post-MPTP. Because of the high degree of challenge of this task, mice of saline injected groups (-MPTP) fed with either a control or HCT1026 diet, performed better on the second trial (+ 1 d) and subsequent days, compared with d -7. By contrast, MPTP-treated mice fed with a control diet exhibited a significant decrease in the mean latency to fall at all timepoints tested, compared to saline-injected mice (p < 0.05), defining a motor deficit in MPTP-treated animals ( Figure  1D). In MPTP mice fed with HCT1026, the mean latency to fall was significantly (p < 0.05) increased compared to MPTP mice fed with a control diet at all time tested. By 7 dpt, HCT1026-fed mice performed as good as the control mice, indicating a significant reduction of the motor impairment by the preventive treatment with HCT1026. Young and ageing C57Bl/6 mice fed with a control, flurbiprofen or HCT1026 diets (30 mg kg -1 ) starting at -10 d, underwent an MPTP treatment according to the subacute (A) or subchronic (B), injection paradigms, as described. Age-matched mice fed with the different diets received physiologic saline (NaCl, 10 ml kg -1 ) and served as controls. Seven days after MPTP discontinuance, loss of DAergic functionality was assessed in striatum measuring high affinity synaptosomial striatal [ 3 DA] uptake [8]. HCT1026 prooved to be more potent than its parent compound in counteracting MPTP-induced decreases in striatal DA uptake levels in both the subacute (A) and subchronic (B) protocols. Differences were analyzed by ANOVA followed by Newman-Keuls test, and considered significant when p < 0.05. **p < 0.05 vs saline,°p < 0.05 vs MPTP + control diet. C. Ageing mice fed with a control or HCT1026 diets, were submitted to the subchronic MPTP regimen, and striatal DA uptake levels measured 21, 30 and 40 d after MPTP (n = 6/time point). Note the long-lasting counteraction of MPTP-induced striatal toxicity in mice fed with HCT1026 as opposed to the control diet. D: Motor performances on Rotarod of saline-and MPTP-treated mice (n = 10/group) fed with a control or HCT1026 diets. Time of permanence on revolving bars (ordinate) are plotted against pre-and post-treatment days (5 trials/day) during which experiments were performed. Mean and SEM values are reported. Establishment of a motor deficit measured 1-7 dpt, is counteracted by HCT1026. Differences were analyzed as above. ** p < 0.05 vs saline;°p < 0.05 vs MPTP + control diet.

HCT1026 inhibits MPTP-induced loss of striatal TH and DAT at mRNA and protein levels
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis and a marker for DA neurons. The dopamine transporter, DAT, is a highly specific marker of projecting DAergic nigrostriatal neurons and thus, its expression is proportional to the loss of striatal dopamine content [76]. Accordingly, we examined TH and DAT striatal expression using RT-PCR, immunohistochemistry coupled to confocal microscopy, and western blot (WB) analyses. RT-PCR of TH (Figure 2A and 2B) and DAT ( Figure 2E and 2F) mRNAs in striatum Figure 2 HCT1026 inhibits MPTP-induced loss of striatal TH and DAT mRNAs expression. Ageing (9-11 month-old) C57Bl/6 mice fed with a control (ct) or HCT1026 diets (30 mg kg -1 ) starting at -10 d, underwent an MPTP treatment according to the subchronic injection paradigm, as described. Age-matched mice fed with the different diets received physiologic saline and served as controls. Mice were sacrificed at different time-intervals after MPTP. Striatal tissue samples were processed for semi-quantitative RT-PCR analysis as described. Total RNA isolated and cDNA synthesized using Retroscript Kit (see Materials and Methods) following the manufacturer's directions. The 250 ng of cDNA were used for PCR, by using Super Taq DNA polymerase with specific primer pairs for TH (620 bp) and DAT (328 bp), and Classic S18 Standard (495 bp). Samples from PCR reactions were separated electrophoretically on 2% agarose gel containing 0,2 μg/ml of ethidium bromide (B-D, F-H). Fluorescent bands of amplified gene products were captured by using Gel Logic 200 Imaging System (Kodak), values normalized against S18 and ratios expressed as percent of control, within each experimental group (A, E). Differences were analyzed by ANOVA followed by Newman-Keuls test, and considered significant when p < 0.05. ** vs saline;°p < 0.   indicated no significant differences in transcript levels in saline-treated mice fed with control or HCT1026 diets. By contrast, exposure to MPTP induced a significant and longlasting decrease of TH mRNA in ageing mice fed with a control diet after either 7, 21 d (Figure 2A and 2C), 30 or 40 d (Figure 2A and 2D). In analogy with these findings, DAT mRNA levels were sharply down-regulated at 7, 21 ( Figure 2E and 2G), 30 and 40 d ( Figure 2E and 2H) post-MPTP in mice fed with a control diet. By contrast, in mice fed with HCT1026, TH and DAT mRNAs (Figure 2A, B, C and 2D) and DAT mRNA (Figure 2E, F, G and 2H) levels were significantly increased compared with those measured in MPTP mice fed with a control diet, thus supporting The data from experimental bands were normalized to β-actin, before statistical analysis of variance. Values are expressed as % of saline-injected controls. Differences were analyzed by ANOVA followed by Newman-Keuls test, and considered significant when p < 0.05. * p < 0.05 compared to saline;°p < 0.05 vs MPTP fed with the control diet. C. Semi-quantitative RT-PCR for iNOS. The 250 ng of cDNA were used for PCR, by using Super Taq DNA polymerase with specific primer pairs for iNOS (500 bp) and Classic GADPH Standard (270 bp). Samples from PCR reactions were processed as described. Fluorescent bands of amplified gene products were analyzed, the values normalized against GADPH and ratios expressed as % of control, within each experimental group (C), see text for details. Differences were analyzed by ANOVA as above. ** p < 0.05 vs saline;°p < 0.05 vs MPTP + control diet.

HCT1026-induced striatal DAergic neuroprotection was maintained at long time intervals.
As observed ( Figure 3A and 3E), average striatal TH-and DAT-immunofluorescent (IF) signal intensity (pixel ± SEM), did not differ in saline-injected mice fed with either control or HCT1026-medicated diets. Subchronic MPTP treatment decreased TH- (Figure 3A and 3C) and DAT-IF ( Figure 3E and 3G). In addition, loss of striatal DAergic innervation lasted up to 40 dpt. By contrast, HCT1026 significantly counteracted the loss of TH ( Figure 3A and 3D)-and DAT ( Figure 3E and 3H)-IF signal intensity, up to 40 dpt. Changes in TH and DAT proteins were next quantified by WB in saline and MPTP mice fed with the control or HCT1026 diet ( Figure 3I and 3J). After 40 d from from MPTP administration, a significant reduction of MPTP-induced downregulation of both markers was observed only in mice fed with HCT1026 diet. These and previous findings support the long-term efficacy of HCT1026 in preserving TH and DAT expression and function in striatum of ageing mice exposed to subchronic MPTP regimen.

MPTP metabolism is not affected by HCT1026 preventive treatment
One of the first limiting factors in MPTP toxicity is the conversion of MPTP into MPP + by means of the monoamine oxidase B (MAO-B) enzymatic activity. MPP+ is known to gain access into neurons via DAT, and through this mechanism it is accumulated into DAergic cells causing selective toxicity [76]. The striatal levels of MPP + were then measured 90 min after MPTP injection in mice fed with the different diets and exposed to MPTP. There was no significant difference in striatal MPP + levels measured 90 min after MPTP injection in mice fed with either the control (110 ± 7 ng mg -1 protein) or HCT1026 (124 ± 12 ng mg -1 protein) diets, thereby indicating that the greater protection afforded by HCT1026 might not be attributed to poor MPP + metabolism.

HCT1026 preventive administration decreases MPTPinduced loss of TH + cell bodies in SNpc
We next assessed the impact of HCT1026 in MPTPinduced toxicity of nigral DAergic cell bodies (Figure 4 and Figure 5). In mice fed with a control diet, MPTP induced a dose-dependent loss of double-stained TH + (revealed by FITC, in green) DAT + (revealed by CY3, in red) cells in SNpc (compare Figure 4A, B and 4C with Figure 4D, E and 4F), whereas MPTP-induced DAergic neurotoxicity was signicantly (p < 0.05) reduced in HCT1026-fed mice ( Figure 4G, H and 4I). Estimation of the total number of TH + Nissl + neurons using the Abercrombie correction, confirmed a dose-dependent reduction of TH + Nissl + neurons in MPTP-treated mice fed with control diet, suggesting an actual TH + neuronal loss rather than loss of TH expression ( Figure 4J). By contrast, HCT1026-fed mice exhibited a significantly greater number of TH + Nissl + neurons at all doses tested ( Figure 4J). These results suggest that a certain number of DAergic neurons could survive the MPTP insult in mice receiving a preventive treatment with HCT1026.
In order to verify the ability of the continous oral treatment with HCT1026 to maintain its neuroprotective effects, saline and MPTP (15 mg kg -1 day-1 per 5 consecutive days), mice fed with the control or HCT1026 diet were sacrificed at 21, 30 and 40 dpt. As observed, at either 7 d ( Figure 5A, B, C and 5M), 21, 30 ( Figure 5M), or 40 dpt ( Figure 5G, H, I and 5M) MPTP mice fed with the control diet did not recover as reflected by the significant, long-lasting loss of TH + Nissl + neurons. In sharp contrast, HCT1026 exerted a significant neuroprotective effect that was maintained up to 40 dpt (see Figure 5D, E, F, and 5J, K, L, M), suggesting increased survival/rescue of SNpc neurons in HCT1026-fed mice.

HCT1026 inhibits MPTP-induced microglial activation
Glial inflammatory mechanisms are thought to contribute to MPTP-induced nigrostriatal DAergic degeneration (see Refs in Background). Indeed, when microglia adopts a pro-inflammatory phenotype, the production and release of a plethora of toxic mediators, including pro-inflammatory cytokines and iNOS-derived NO, can enhance neuronal damage in the SNpc and accelerate the appearance of behavioral symptoms [32,[81][82][83]. The ability of HCT1026 to modulate MPTP-induced microglial activation was next assessed during the early phase of active degeneration [8] using immunohistochemistry, WB and RT-PCR analysis.

Microglial cell number/morphology in striatum and SNpc
Changes in activated microglial cell number and morphologic appearance at both striatal and SNpc levels were assessed using Mac-1-Ab, an integrin receptor known to mediate reactive microgliosis and recognized to significantly contribute to the progressive dopaminergic neurodegeneration in the MPTP model of DAergic toxicity, both in vivo and in vitro [see [28][29][30][31][32][33] and background]. In saline-injected mice fed with either control or HCT1026 diets, Mac-1 + -microglial cells with elongated cell bodies and ramified processes were present. As previously shown, an increased number of Mac1 + cells with morphological characteristics of activated microglia (i.e. ameboid, round shaped Mac1 + cells with thick and short processes) was observed in both striatum ( Figure 6A, C, D and inset) and SNpc ( Figure 6H, J, K and inset) levels. By contrast, Mac-1 + cells exhibited a more elongated cell body with longer and thinner processes in mice fed with HCT1026 diet (see insets in Figure 6G and 6N). Moreover, the number of ameboid-like Mac-1 + cells was sharply reduced both in striatum (Figure 6A, F and 6G) and midbrain ( Figure 6H, M and 6N) of HCT1026-fed mice.

Mac-1 and PHOX expression in the ventral midbrain (VM)
Mac-1 is linked to the activation of PHOX, a chief component of MPTP-dependent microglia activation [29][30][31][32][33]. Given that Mac-1 and PHOX act in a synergistic way, and are essential to enhance DAergic degeneration, we next evaluated the expression of both markers within the ventral midbrain by WB, during the maximal phase of glia activation [8]. As previously observed, a sharp increase of Mac-1 and PHOX followed MPTP treatment, as early as 1 dpt, in mice fed with the control diet, with levels remaining high at both 3 and 7 dpt ( Figure 7A, B). Conversely, HCT1026 significantly reduced MPTP-induced Mac-1 and PHOX expression in the ventral midbrain, supporting reduced microglial activation during the early phase of DAergic degeneration ( Figure 7A, B).

Expression of pro-inflammatory mediators: iNOS and 3-NT
The ability of a preventive treatment with HCT1026 to inhibit MPTP-induced up-regulation of iNOS was next evaluated by semi-quantitative RT-PCR analysis 1 d after MPTP challenge. Within the ventral midbrain of salinetreated mice fed with a control or HCT1026 diet, no significant difference was observed in iNOS mRNA levels, whereas MPTP significantly up-regulated iNOS transcription ( Figure 7C). On the other hand, the MPTP mice fed with HCT1026 exhibited significantly less iNOS mRNA expression compared to controls ( Figure 7C).
When glial superoxide generated by PHOX activation and iNOS/NO are concomitantly active, peroxynitrite (ONOO-), and consequently protein tyrosine nitration and hydroxyl radicals over-production occurs [33]. Hence, the generation of high NO concentration followed by the production of peroxynitrite may be involved in DAergic neuronal cell death. We thus used immunohistochemistry to localize iNOS and 3-nitrotyrosine (3-NT) as fingerprint of iNOS-derived NO and peroxynitrite generation. Dual immunostaining with iNOS and Mac-1 within the SNpc of MPTP mice fed with a control diet, indicated that a significant proportion of reactive Mac-1 cells expressed iNOS, 1-7 d post-MPTP ( Figure 7D, E). Dual staining with 3-NT-and TH indicated a sharp increase in the percentage of TH + cells colocalizing with 3-NT at both 1 and 3 d post-MPTP ( Figure 7G, H), while a certain decrease was observed 7 dpt. Conversely, in MPTP mice fed with HCT1026, both iNOS- (Figure 7D, F) and 3-NT-( Figure 7G, I) were significantly downregulated 1-7 dpt within the SNpc.
These results indicated an efficient reduction of MPTP-induced microglial activation, pro-inflammatory marker expression, i.e. Mac-1, PHOX, iNOS and 3-NT formation within the SNpc of mice fed with HCT1026, which might account for the observed nigrostriatal protection.

Discussion
Grafting a NO-donating moiety into the structure of flurbiprofen, one of the most potent non-selective antiinflammatory agents, yielded a drug devoided of side toxicity and endowed with a remarkable neuroprotective activity against MPTP-induced DAergic neurotoxicity, motor impairment and microglia activation in ageing mice. HCT1026 was effective in both the acute and subchronic models of MPTP, and its neuroprotective activity lasted up to 40 d, as opposed to age-matched controls indicating the longterm safety and efficacy of the HCT1026, as opposed to flurbiprofen. The different outcome of mice treated with HCT1026 was not due to differences in daily food consumption, or to poor MPP + metabolism. HCT1026-induced neuroprotection was associated with a marked down-regulation of activated microglial cell number and a signiof ficant decrease of MPTP-induced pro-inflammatory mediators, including iNOS, Mac-1 and PHOX expression, as well reduced 3-NT formationin SNpc DAergic neurons, suggesting that a switch in microglia pro-inflammatory phenotype might contribute to nigrostriatal neuroprotection.
The experimental study was designed to compare the oral activity of HCT1026 with that of flurbiprofen. However, due to the significant gastric toxicity of flurbiprofen observed in the short-term study, only HCT1026-medicated diet was further studied. In long-term experimental protocols, HCT1026 proved to have a safe profile and a significant efficacy in counteracting MPTP-induced striatal DAergic toxicity.
Nitric oxide (•NO) is a biological molecule known to play a major role in a wide variety of physiological and pathological conditions [84]. Some of its functions include vasodilation of blood vessels, GI mucosal healing and defense. Therefore NSAIDs containing NO-donor groups have been developed to obtain effective treatment of inflammation with reduced GI side effects [57][58][59][60][61]. Indeed, grafting an organic nitrate moiety onto the NSAID scaffold has been shown to result in the release of NO through slow kinetics (in comparison with others NO donors, i.e. sodium nitroprusside, Snitroso-N-acetyl-D,L, penicillamine), possibly mimicking the physiological levels of NO produced by constitutive NO synthases. Thanks to NO release, and the combination of a balanced inhibition of the two main COX isoforms, NO-NSAIDs are endowed with little gastrointestinal and renal toxicity compared to their parents compounds [56][57][58][59][60][61]65,85]. It is believed that the NO, which is released by the metabolism of nitrate as the compounds are broken down, may counteract the consequences of the NSAID-induced decrease in gastric mucosal PGs [65]. It seems important to mention that a clear identification of the metabolic steps by which NO-NSAIDs produce NO has not been established. Experimental findings obtained, in vivo, show that HCT1026 is metabolized into flurbiprofen and NO species, i.e. nitrates and nitrites, [60,61,70], which are detected in plasma and in brain at 2-4 h [70] and 3 h [86], respectively from drug administration. In vitro, HCT1026 is converted into flurbiprofen with different kinetics depending on the cell assay. In rat plasma, 30 min of incubation is required to fully convert HCT1026 to flurbiprofen [see [63]]. By contrast, approximately 35% of HCT1026 is converted into flurbiprofen within 1 h of incubation in human blood, and 24 h of incubation was necessary to reach the almost complete dissociation of HCT1026 [62,63]. Given the rapid action of HCT1026 demonstrated in vitro, Bernardo et al. [63] suggested the possibility that HCT1026 might reach the brain parenchyma and act on brain cells before being cleaved to the nitrate moiety and flurbiprofen [63]. Alternatively, the metabolites flurbiprofen and NO might act concomitantly by activating parallel pathways that ultimately determine the unique effects of HCT1026 [63]. Other studies have suggested a potential action of the HCT-1026 metabolite, 4-hydroxybutyl nitrate, since animal studies have shown that the level of inorganic nitrite in the brain increases after oral administration of HCT-1026 [86]. Plasma nitrite itself has been shown to provide a source of NO under certain conditions [see [87]].
Neurochemical, morphological and behavioral changes clearly indicate that with the ageing process, increased vulnerability of the nigrostriatal DAergic system and limited recovery from MPTP injury are observed [4,5,17,18,77,78]. Indeed, the nigrostriatal DAergic neurons exhibit compensatory mechanisms in response to MPTP injury, but the degree of plasticity becomes reduced with age [18,77,78]. Accordingly, a diminished compensatory capacity of nigrostriatal DAergic neurons "as a prelude" to PD is recognized to accompain the process of aging [see [88,89]]. Among the mechanisms at play, increased neuronal vulnerability to degenerative conditions, dysfunction of glia-neuron crosstalk, reduced repair capacity of injured DAergic neurons and/or limited neurogenesis may contribute to the poor recovery observed with age [see [18] for review]. Given the role of the ageing process as a critical risk factor for developing PD, we addressed the efficacy of HCT1026 preventive administration schedule in 9 to 11 month-old mice and found that longterm administration of HCT1026 resulted in a significant DAergic neuroprotection following MPTP insult, at both and SNpc levels. These effects lasted up to 40 dpt, supporting HCT1026 as promising approach towards the development of effective pharmacological neuroprotective strategies against PD.
On the other hand, Ibuprofen, a non selective blocker, was shown to diminish the decline of dopamine content in striatum in the MPTP mouse model of PD, in a dose-dependent manner, and was not toxic to the DAergic system [41]. In accord with these experimental results, ibuprofen, but not other non-selective NSAIDs, was shown to diminish the risk/incidence of PD in men [5,6]. The present results showing the longterm DAergic neuroprotection in ageing mice and the safety profile of HCT1026 are of special interest, given that non-selective NSAIDs long-term therapies are hampered by their significant gastrointestinal, renal and cardiovascular sideeffects [56,85].
HCT1026-induced neuroprotection observed in the present study was accompanied by a sharp downregulation of all studied markers of microglial activation including ameboid-like microglial cell number, proinflammatory mediators as well as two key harmfull elements, MAC-1 and PHOX, likely suggesting that a shift from microglial pro-inflammatory ("harmfull") phenotype might be a major contributing factor.
Although NSAIDs pharmacological actions are related to their ability to inhibit PG biosynthesis, some of their beneficial therapeutical effects are thought to be mediated by a panel of COX-independent mechanisms. NSAIDs are able to inactivate the transcription NF-kB and activator protein-1 (AP-1), critically involved in the induction of multiple inflammatory gene products involved in the inflammatory response (i.e. iNOS, TNFα). In addition, NSAIDs in neuronal cells might directly and dose-dependently scavenge ROS and RNS, thereby blocking their detrimental effects [45,46]. On the other hand, high concentrations of NSAIDs such as ibuprofen and indomethacin, activate PPARγ. PPARγ is a ligand activated inhibitory transcription factor that antagonizes the activity of NFkB, AP1, signal transducer and activator of transcription-1 (STAT-1) and nuclear factor of activated T cells (NFAT). PPARγ activation is then associated with a reduction in the expression of several inflammatory genes and the production of inflammatory cytokines and iNOS [45,46]. In particular, in vitro studies have reported that selective PPARγ agonists such as pioglitazone, ibuprofen, or indomethacin, can activate PPARγ in microglia, decreasing the number of activated glial cells [see [45,46]].
The mechanisms that differentiate HCT-1026 from flurbiprofen remains a matter of debate. In vitro studies demonstrated that a low concentration of (1 μM) of HCT1026, but not flurbiprofen, activated PPARγ in primary cultures of rat microglia, with kinetics similar to those of the synthetic agonist, ciglitazone [63], supporting additional anti-inflammatory action through PPARγ [63]. In addition PPARγ agonists were reported to mitigate MPTP-induced DAergic neurotoxicity in different PD models [see [13][14][15]45,46]]. In the recent studies of Abdul-Hay et al. [87], flurbiprofen was 10-fold less potent than HCT-1026 in inhibiting iNOS induction in RAW 264.7 cell cultures. In LPS/IFNγ-induced primary astroglial cultures, HCT-1026 showed anti-inflammatory potency towards inhibition of cytokine and iNOS elevation, providing similar observations to those in microglial cultures [62]. That the anti-inflammatory activity of HCT-1026 could translate into neuroprotection was further demonstrated in a co-culture experiment with LPS-stimulated RAW cells and a neuroblastoma cell culture, where HCT-1026 was highly efficacious neuroprotectant [87].
It should be recalled, that NO signaling plays an important role in the functioning of the CNS, and activation of soluble guanylate cuclase (sGC) represent one important effect of NO. Of note, physiological release of low concentrations of NO by constitutive neuronal NOS is recognized to modulate extracellular levels of dopamine in the striatum and to critically participate in striatal DAergic homeostasis [98]. The NO/sGC/cGMP signal transduction system is also considered to be important for modulating synaptic transmission and plasticity in brain regions such as the hippocampus, cerebral cortex, and cerebellum, and further studies are required to unravel potential involvement of these pathways in DAergic neuroprotection afforded by HCT1026.
Besides the NO-mediated effects, most recently proposed are NO-independent and NSAID-independent actions on NFB and MAPK/ERK signaling pathways [see [64]]. In their study, Idris and co [64] reported the ability of HCT1026 to inhibit receptor activator of NFkB (RANKL), as well as RANKL-induced activation of NFkB and ERK pathway in LPS-stimulated macrophage cultures. In addition, HCT1026 also inhibited TNF-α, IL-1 and LPS-induced signaling. Interestingly enough, the pathways inhibited by HCT1026 all share a similar kinase complex upstream of the NFkB and ERK pathways and this is the most likely target for the action of HCT1026 [64].
It seems important to underline that inflammatory pathways may become hyperactivated with age and/or become more sensitive to immune/neurotoxic challenge, thereby promoting degeneration [99][100][101][102]. Given that with age, dysfunctional microglia and altered glia-neuron crosstalk may contribute to the progression of neuronal degeneration [18], HCT1026 preventive and long-term treatment might thus reduce age-dependent and MPTPinduced increase in oxidative and inflammatory attacks to nigrostriatal DAergic neurons. Of special interest, in view of the role of both systemic and central inflammation in modulating the severity of neuronal insult, including DAergic injury [see [13][14][15]18,24,[81][82][83]], a potential effect of HCT1026 in influencing systemic inflammation cannot be excluded. In addition, the mitigation of the nitrosative/oxidative status of the nigral microenvironment as revealed by downregulation of Mac-1, PHOX and 3-NT in the VM, likely have beneficial consequences for glial expression of critical neuroprotective/neurotrophic factors [18], thereby supporting TH + neuron survival/neurorescue, possibly through an amelioration/ mitigation of SNpc nicroenvironment. After brain injury, the inflammatory environment is recognized to have both detrimental and beneficial effects on neuronal outcome, depending on mouse strain, age and sex of the host, the severity of the lesion, the degree and timing glial activation, the hormonal background, the specific cellular context and intrinsic region-specific neuronal characteristics [see [8][9][10][11][12][13][14][15][16][17][18][21][22][23][24][25][26]40,77,78,100,103,104]]. In degenerative conditions, glia serve neuroprotective functions including the removal of dead cells by phagocytic activity and the production of neurotrophic factors. By contrast, overactivation of microglia or dysfunctional microglial cells as a consequence of ageing and agerelated events within the SN microenviroment, [18,25,[100][101][102] likely increase DAergic neuron vulnerability and/or may limit DAergic self-repair abilities. In vivo experiments have recently shown that intranigral administration of prostaglandin J2 (PJ2) induces microglia activation, selective degeneration of DAergic neurons in the SNpc, formation of ubiquitin-and α-synuclein-immunoreactive aggregates in the spared DAergic neurons, and locomotor deficit [83]. These and other findings have underlined the role of a transient initiation factor, triggering an active self-perpetuating cycle of chronic neuroinflammation, contributing to DAergic neuronal dysfunction [13,83]. By reducing exacerbation of inflammation, HCT1026 may then improve mitochondrial performance, increase glial-mediated neurotrophic support, thus creating a more favorable milieu for nigrostriatal DAergic neuron survival/rescue.
The present results are in line with data obtained in different animal models of brain inflammation, where HCT1026 significantly reduced neuronal loss and decreased the number of reactive microglial cells to a greater extent than the parent compound, flurbiprofen [66,86,87,92,93]. In experimental allergic encephalomyelitis (EAE), oral treatment with HCT1026 which delayed disease onset and decreased the severity of clinical signs in mice immunized with myelin oligodendrocyte peptide (MOG35-55) [66]. In addition, HCT1026 fed mice exhibited significantly reduced mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells, with reduced number of CNS-infiltrating T cells [66]. Recently, HCT1026 was reported to mitigate amyloid-β-induced toxicity, in cell culture, in vitro, while enhancing cognition in response to cholinergic blockade, in vivo [87]. Other studies reported the ability of HCT1026 to reduce microglia activation and to prevent muscular dystrophy pathology in two murine models [93].

Conclusions
We herein report that oral preventive administration of the NO-donating derivative of flurbiprofen, HCT1026, has a safe profile and a significant efficacy in counteracting MPTP-induced DAergic neurotoxicity, motor impairment and microglia activation in ageing mice. In particular, nigrostrial DAergic neuroprotection afforded by HCT1026 lasted for 40 d after MPTP administration. Hence, DAergic neurons exhibited an increased ability to resist to the cytotoxic environment caused by MPTP injury, leading to a significant neurorescue observed within the striatum and SNpc, at a morphological, neurochemical, and molecular levels. These effects of HCT1026 were associated with reduced microglial proinflammatory phenotype and reduced formation of the peroxynitrite footprint, 3-NT, within TH + cell bodies. While further studies are required to clarify the mechanism(s) of HCT1026 neuroprotective effects, the combination of a balanced inhibition of the two main COX isoforms with NO release provides a promising approach towards the development of novel and effective therapeutic strategies against PD.